GH vs. SNN: Guardant Health vs. Smith & Nephew Stock Comparison

Company Profile

Guardant Health (GH) and Smith & Nephew (SNN) both fall under the Health Care Equipment & Services industry group, but GH is classified in Health Care Providers & Services while SNN is classified in Health Care Equipment & Supplies.

Guardant Health (GH) trades as ordinary local shares, while Smith & Nephew (SNN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Guardant Health (GH) has an aggressive beta of 1.69, indicating higher sensitivity to broad-market moves, while Smith & Nephew (SNN) is defensive at 0.49 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Smith & Nephew (SNN) earns 11.85% on shareholders’ equity, ranked against its industry; Guardant Health (GH) has no ROE this period.

Guardant Health (GH) reports a negative net margin of -37.93%, usually indicating a net loss over the period. Meanwhile Smith & Nephew (SNN) reports 10.08%, ranking against industry peers normally.

Guardant Health (GH) reports a negative operating margin of -37.06%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Smith & Nephew (SNN) reports 14.47%, ranking against industry peers normally.

Profitability Metrics

Growth

Guardant Health (GH) at 32.88% sits in the top revenue growth quartile, while Smith & Nephew (SNN) at 6.09% is closer to the peer norm — faster top-line expansion for GH.

Only one side can be read here: Smith & Nephew (SNN) reports EPS growth of 52.34%, ranked against its industry; Guardant Health (GH) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Guardant Health (GH) at 3.60 and Smith & Nephew (SNN) at 2.14 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Only one side’s leverage can be read here: Smith & Nephew (SNN) carries debt-to-equity ratio of 0.73 against its industry range, while Guardant Health (GH) reports no figure this period.

Financial Strength Metrics

Dividends

Guardant Health (GH) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Smith & Nephew (SNN) reports a yield of 1.24%, ranking against industry peers normally.

Guardant Health (GH) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Smith & Nephew (SNN) reports a payout of 53.20%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Smith & Nephew (SNN) trades at 21.19 times trailing earnings, ranked against its peers, while Guardant Health (GH) has no P/E ratio this period.

Smith & Nephew (SNN) at 2.07 prices around its industry’s typical P/S ratio, while Guardant Health (GH) at 15.96 clears its benchmark range — GH looks notably rich on sales.

Guardant Health (GH) reports a negative P/B ratio of -73.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Smith & Nephew (SNN) reports 12.80, ranking against industry peers normally.

Valuation Metrics